Long-Term Predictors of Clinical Events after Off-Label Use of Drug-Eluting Stent beyond 1 Year |
Yun, Kyeong Ho
(Department of Cardiovascular Medicine, Regional Cardiovascular Center, Wonkwang University Hospital)
Ko, Jum Suk (Department of Cardiovascular Medicine, Regional Cardiovascular Center, Wonkwang University Hospital) Rhee, Sang Jae (Department of Cardiovascular Medicine, Regional Cardiovascular Center, Wonkwang University Hospital) Lee, Eun Mi (Department of Cardiovascular Medicine, Regional Cardiovascular Center, Wonkwang University Hospital) Yoo, Nam Jin (Department of Cardiovascular Medicine, Regional Cardiovascular Center, Wonkwang University Hospital) Kim, Nam-Ho (Department of Cardiovascular Medicine, Regional Cardiovascular Center, Wonkwang University Hospital) Oh, Seok Kyu (Department of Cardiovascular Medicine, Regional Cardiovascular Center, Wonkwang University Hospital) Jeong, Jin-Won (Department of Cardiovascular Medicine, Regional Cardiovascular Center, Wonkwang University Hospital) |
1 | Katritsis DG, Korovesis S, Tzanalaridou E, Giazitzoglou E, Zografos T, Meier B. Spot drug-eluting stenting for long coronary stenoses: longterm results of a randomized clinical study. J Interv Cardiol 2011;24:437-41. DOI |
2 | Dawkins KD, Grube E, Guagliumi G, et al. Clinical efficacy of polymerbased paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-13. DOI |
3 | Colombo A, De Gregorio J, Moussa I, et al. Intravascular ultrasoundguided percutaneous transluminal coronary angioplasty with provisional spot stenting for treatment of long coronary lesions. J Am Coll Cardiol 2001;38:1427-33. DOI |
4 | Katritsis DG, Korovesis S, Tzanalaridou E, Giazitzoglou E, Voridis E, Meier B. Comparison of long versus short ("spot") drug-eluting stenting for long coronary stenoses. Am J Cardiol 2009;104:786-90. DOI |
5 | Planer D, Beyar R, Almagor Y, et al. Long-term (>3 Years) outcome and predictors of clinical events after insertion of sirolimus-eluting stent in one or more native coronary arteries (from the Israeli arm of the e-Cypher registry). Am J Cardiol 2008;101:953-9. DOI |
6 | Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010;56:1897-907. DOI |
7 | Lee CW, Park SJ. Predictive factors for restenosis after drug-eluting stent implantation. Korean Circ J 2007;37:97-102. DOI |
8 | Brodie BR, Stuckey T, Downey W, et al. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group. JACC Cardiovasc Interv 2008;1:405-14. DOI |
9 | Park K, Park KW, Rha SW, et al. Comparison of 5-year clinical outcomes between sirolimus-versus paclitaxel-eluting stent: Korean multicenter network analysis of 9000-patient cohort. Circ Cardiovasc Interv 2012; 5:174-84. DOI |
10 | Park KW, Kim CH, Lee HY, et al. Does "late catch-up" exist in drug-eluting stents: insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents. Am Heart J 2010;159:446-53. DOI |
11 | Ko YG, Kim JS, Choi D, et al. Five-year outcomes of sirolimus-eluting versus paclitaxel-eluting stents: a propensity matched study: clinical evidence of late catch-up? Int J Cardiol 2011;152:302-6. DOI |
12 | Weisz G, Leon MB, Holmes DR Jr, et al. Five-year follow-up after sirolimus- eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009;53:1488-97. DOI |
13 | Kandzari DE, Mauri L, Popma JJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2011;4:543-50. DOI |
14 | Nikol S, Huehns TY, Hofling B. Molecular biology and post-angioplasty restenosis. Atherosclerosis 1996;123:17-31. DOI |
15 | Kim YH, Park SW, Lee SW, et al. Sirolimus-eluting stent versus paclitaxel- eluting stent for patients with long coronary artery disease. Circulation 2006;114:2148-53. DOI |
16 | Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drugeluting stents. Lancet 2004;364:583-91. DOI |
17 | Serruys PW, Daemen J, Morice MC, et al. Three-year follow-up of the ARTS-II# - sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. EuroIntervention 2008;3:450-9. DOI |
18 | Suh J, Park DW, Lee JY, et al. The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation. JACC Cardiovasc Interv 2010;3:383-9. DOI |
19 | Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23. DOI |
20 | Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31. DOI |
21 | Beohar N, Meyers SN, Erdogan A, et al. Off-label use of drug-eluting versus bare metal stents: a lesion-specific systematic review of longterm outcomes. J Interv Cardiol 2010;23:528-45. DOI |
22 | Serruys PW, Onuma Y, Garg S, et al. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimuseluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol 2010;55:1093-101. DOI |
23 | Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009;2:1248-59. DOI |
24 | Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007; 297:2001-9. DOI |
25 | Caixeta A, Leon MB, Lansky AJ, et al. 5-year clinical outcomes after sirolimus- eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol 2009;54:894-902. DOI |
![]() |